ESR1 and breast carcinoma: Nowadays, more and more women have gained resistance to endocrine therapy, resulting a relapse of breast cancer.35 Results from our study supported the scientific evidence that palbociclib had high activity in ER‐positive and HER2‐negative breast cancer lines.